Zenas Bio rises as Wedbush launches with Outperform on lead asset
Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush launched the newly IPO’ed biotech's coverage with an ...
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused ...
Nasdaq1 个月
Zenas BioPharma Advances Obexelimab Trials and Out-licenses Thyroid Eye Disease Programs in ...
Zenas BioPharma announced advancements in the clinical development of obexelimab, a novel CD-19 x FcγRIIb inhibitor targeting B cell function, with key trial results expected in 2025. The Phase 2 ...
Wedbush bullish on Zenas BioPharma, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...
bernama1 个月
Zenas BioPharma Targets Key 2025 Milestones For Obexelimab In Autoimmune Diseases
(US$1=RM4.41) Zenas Founder and Chief Executive Officer, Lonnie Moulder highlighted the company’s progress across various goals in 2024, noting that it enters 2025 with major milestones in sight, ...
Nasdaq6 天
Zenas BioPharma Appoints Dr. Lisa von Moltke as Head of Research and Development and Chief ...
von Moltke's leadership, particularly as the company progresses with clinical trials for their lead product, obexelimab, aimed at treating diseases like multiple sclerosis and systemic lupus ...